Drug intelligence / Profile preview

MP0260

Development stage: Preclinical
Lead developer: Molecular Partners
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

**MP0260** is a small therapeutic protein engineered as a DARPin (Designed Ankyrin Repeat Protein) with dual inhibitory activity against all relevant isoforms of **vascular endothelial growth factor A (VEGF-A)** and **platelet-derived growth factor B (PDGF-B)**. Developed by **Molecular Partners AG** and exclusively licensed to **Allergan (AbbVie)**, it targets neovascular eye diseases by blocking VEGF-A-mediated angiogenesis and PDGF-B-driven pericyte recruitment and fibrosis, potentially offering improved efficacy over single-target anti-VEGF therapies for conditions like exudative age-related macular degeneration (wet AMD) and related retinal disorders.[1][3][5][7]

Targets

PDGFB (PDGF-B)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on MP0260.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP0260.

Explore the full profile